Approval · Notice of Compliance 25236 · 2021
ARIXTRA: Notice of Compliance 25236
Issued February 17, 2021
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 25236
- Date
- February 17, 2021
- Company
- Aspen Pharmacare Canada Inc.Oakville, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- To add a label on the new blister packaging component for 2.5 mg/ 0.5 mg and 7.5 / 0.6 ml
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| ARIXTRA | Not yet assigned | — |
Medicinal ingredients
- FONDAPARINUX SODIUM 2.5 MG per 0.5ML
- FONDAPARINUX SODIUM 7.5 MG per 0.6ML